Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Exclusion Criteria

• •History of any of the following within 60 days prior to or during screening: Type I (spontaneous) MI, valvular replacement or repair, coronary revascularization, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke.
• •HF due to: hypertrophic cardiomyopathy, infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, arrhythmogenic right ventricular or left ventricular cardiomyopathy/dysplasia, uncorrected primary valvular heart disease, clinically significant congenital heart disease.
• •Any lifetime history of LVEF ≤ 40%.
• •Hospitalized with acute decompensated HF at the time of or during the screening period.
• •Type 1 diabetes mellitus, or any type of diabetes with the exception of T2DM or history of gestational diabetes.
• •For participants with a prior diagnosis of T2DM (including those diagnosed during screening):
• •1. HbA1c \> 10.0% (86 mmol/mol) at screening
• •2. Uncontrolled diabetes requiring immediate therapy
• •3. History of diabetic ketoacidosis or hyperosmolar state/coma within 12 months before randomization
• •4. One or more episodes of severe hypoglycemia within 6 months before randomization and/or history of hypoglycemia unawareness
• •5. History or presence of either proliferative diabetic retinopathy, or diabetic maculopathy, or severe non-proliferative diabetic retinopathy; or currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
• •SBP ≥ 180 mmHg during the screening period, or on three or more blood pressure-lowering drugs with a SBP \> 160 mmHg during the screening period.
• •History of chronic pancreatitis or acute pancreatitis in the 180 days before screening or during the screening period.
• •Any personal lifetime history of, or family history(first-degree relative\[s\]) of medullary thyroid carcinoma or MEN-2.
• •eGFR \< 20 mL/min/1.73 m\^2 (CKD-EPI creatinine (Cr)-cystatin C equation) or receiving dialysis at screening.
• •Calcitonin ≥ 50 ng/L (pg/mL) at screening.
• •Acute or chronic hepatitis.
• •Any of the following psychiatric history:
• •1. History of unstable major depressive disorder or other severe psychiatric disorder within 2 years prior to screening or during the screening period
• •2. Lifetime history of suicide attempt
• •3. History of non-suicidal self-injury within 5 years prior to screening or during the screening period.
• •History of any other condition that, in the opinion of the investigator, may preclude the participant from following the protocol and completing the trial.
• •Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days prior to or during the screening period or planned use during the conduct of the trial.